Clinical Trial: Tipifarnib in Treating Patients With Myeloproliferative Disorders
Study Status: Terminated
Recruit Status: Unknown status
Study Type: Interventional
Official Title: Phase I/II Study of the Farnesyltransferase Inhibitor R115777 (NSC 702818) in Patients With Myeloproliferative Disorders
Brief Summary:
RATIONALE: Tipifarnib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
PURPOSE: This phase I/II trial is studying the side effects of tipifarnib and to see how well it works in treating patents with myeloproliferative disorders.
Detailed Summary:
OBJECTIVES:
- Determine the toxic effects of tipifarnib in adult patients with myeloproliferative disorders.
- Determine hematological responses, including changes in WBC count and erythroid responses, in this patient population treated with this drug.
- Determine the cytogenetic response in bone marrow of patients treated with this drug.
OUTLINE: This is a multicenter study. Patients are stratified according to prior substantive treatment (yes vs no).
Patients receive oral tipifarnib twice daily on days 1-21. Treatment repeats every 4 weeks for a maximum of 4 courses in the absence of unacceptable toxicity or disease progression. Patients with continued hematologic response after completion of the fourth course may receive additional courses at the discretion of the investigator.
PROJECTED ACCRUAL: A total of 25 patients (12-13 per stratum) will be accrued for this study within 25 months.
Sponsor: Stanford University
Current Primary Outcome:
Original Primary Outcome:
Current Secondary Outcome:
Original Secondary Outcome:
Information By: National Cancer Institute (NCI)
Dates:
Date Received: June 2, 2000
Date Started: June 2000
Date Completion:
Last Updated: June 4, 2011
Last Verified: July 2005
